Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 4/20 | 0.58 |
| ▸ | PDE2A | O00408 | 10/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333147 | 1.00 | METAP2 (0.58) | METAP2PDE2AMKNK1MKNK2PDE3B | |
| SCHEMBL12125338 | 0.86 | METAP2 (0.58) | METAP2PDE2APDE3BPDE3APREP | |
| SCHEMBL12125329 | 0.81 | METAP2 (0.58) | METAP2MKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL1333582 | 0.80 | METAP2 (0.52) | METAP2PDE2APDE3BPDE3APREP | |
| SCHEMBL7903221 | 0.80 | METAP2 (0.70) | METAP2PDE2APDE3A | |
| SCHEMBL2493834 | 0.79 | MKNK1 (0.42) | METAP2MKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL1331872 | 0.79 | METAP2 (0.60) | METAP2PDE2APDE3BPDE3APREP | |
| SCHEMBL1332343 | 0.79 | METAP2 (0.60) | METAP2PDE2APDE3BPDE3APREP | |
| SCHEMBL1331506 | 0.77 | METAP2 (0.55) | METAP2PDE2APDE3BPDE3APREP | |
| SCHEMBL7903285 | 0.77 | METAP2 (0.60) | METAP2PDE2APDE3AEGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379558-B1 | NOVEL HETEROCYCLIC COMPOUNDS FOR USE AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-03-23 | — | — | EP | claimed |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | claimed |
| EP-2379558-B1 | NOVEL HETEROCYCLIC COMPOUNDS FOR USE AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-03-23 | — | — | EP | disclosed |
| EP-2379558-B1 | NOVEL HETEROCYCLIC COMPOUNDS FOR USE AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-8546406-B2 | Heterocyclic compounds as metap-2 inhibitors | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546406-B2 | Heterocyclic compounds as metap-2 inhibitors | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546406-B2 | Heterocyclic compounds as metap-2 inhibitors | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | disclosed |
| EP-2379558-A1 | NOVEL HETEROCYCLIC COMPOUNDS FOR USE AS METAP-2 INHIBITORS | Merck Patent GmbH (DE) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010083870-A1 | NOVEL HETEROCYCLIC COMPOUNDS FOR USE AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010083870-A1 | NOVEL HETEROCYCLIC COMPOUNDS FOR USE AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | METAP2, METAP1, XPNPEP2 | METAP2 1/4885PDE2A 2740/4885MKNK1 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.